Jenscare Scientific Co. Ltd. Class H (HK:9877)
:9877
Want to see HK:9877 full AI Analyst Report?
9877 Stock Chart & Stats
HK$9.48
HK$0.16(3.97%)
At close: 4:00 PM EST
HK$9.48
HK$0.16(3.97%)
Day’s Range― - ―
52-Week RangeHK$6.76 - HK$11.98
Previous CloseN/A
Volume216.80K
Average Volume (3M)805.10K
Market Cap
HK$3.91B
Enterprise ValueHK$2.12B
Total Cash (Recent Filing)HK$527.63M
Total Debt (Recent Filing)HK$47.38M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume637,060
30 Day Avg. Volume805,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Bulls Say, Bears Say
Bulls Say
High Gross Margins / Unit EconomicsSustained gross margins near 75% indicate attractive unit economics for Jenscare’s transcatheter devices. High product-level margins provide structural flexibility to absorb SG&A and R&D while scaling, supporting long-term profitability if revenue growth continues.
Light Financial LeverageA very low debt-to-equity ratio (~0.06) reduces solvency risk and interest burden, giving management optionality to fund expansion through equity or modest borrowing. This balance-sheet strength supports a multi-quarter runway to commercialize products.
Rapid Revenue Ramp / Commercialization TractionA sharp revenue ramp to ~88M demonstrates that Jenscare is converting R&D into commercial sales and gaining market access. Continued top-line expansion is a durable indicator of product-market fit and potential scale benefits over several quarters.
Bears Say
Large Ongoing Net LossesA net loss of roughly 264M in 2025 shows operating costs far exceed current revenues, implying a multi-quarter path to sustainable profitability. Persistent large losses can erode capital, constrain strategic choices, and require recurring external financing.
Negative Operating And Free Cash FlowMaterial negative OCF and FCF (~-75M and -80M) reflect cash burn despite improving revenue. Continued negative cash conversion requires external funding, creating dilution risk or spending constraints that can limit R&D, commercial rollout, or competitive response.
Negative Returns On EquityA ROE near -33% signals the company is destroying shareholder capital currently. If persistently negative, poor returns undermine investor support and make accessing new capital more costly, impairing long-term strategic initiatives and growth investments.
Jenscare Scientific Co. Ltd. Class H News
9877 FAQ
What was Jenscare Scientific Co. Ltd. Class H’s price range in the past 12 months?
Jenscare Scientific Co. Ltd. Class H lowest stock price was HK$6.76 and its highest was HK$11.98 in the past 12 months.
What is Jenscare Scientific Co. Ltd. Class H’s market cap?
Jenscare Scientific Co. Ltd. Class H’s market cap is HK$3.91B.
When is Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date?
Jenscare Scientific Co. Ltd. Class H’s upcoming earnings report date is Sep 02, 2026 which is in 70 days.
How were Jenscare Scientific Co. Ltd. Class H’s earnings last quarter?
Jenscare Scientific Co. Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.29 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.29.
Is Jenscare Scientific Co. Ltd. Class H overvalued?
According to Wall Street analysts Jenscare Scientific Co. Ltd. Class H’s price is currently Overvalued.
Does Jenscare Scientific Co. Ltd. Class H pay dividends?
Jenscare Scientific Co. Ltd. Class H does not currently pay dividends.
What is Jenscare Scientific Co. Ltd. Class H’s EPS estimate?
Jenscare Scientific Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jenscare Scientific Co. Ltd. Class H have?
Jenscare Scientific Co. Ltd. Class H has 310,306,200 shares outstanding.
What happened to Jenscare Scientific Co. Ltd. Class H’s price movement after its last earnings report?
Jenscare Scientific Co. Ltd. Class H reported an EPS of -HK$0.29 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.222%.
Which hedge fund is a major shareholder of Jenscare Scientific Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jenscare Scientific Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
201.35%
12-Months-Change
Fundamentals
Return on Equity
-22.25%
Trailing 12-Months
Asset Growth
-8.72%
Trailing 12-Months
Company Description
Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.
Technical Analysis
Peijia Medical Ltd.
―
LifeTech Scientific Corporation
―
Shanghai Kindly Medical Instruments Co., Ltd. Class H
―
AK Medical Holdings Ltd.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---